Healthcare Triangle underwent extreme dilutive capital restructuring with multiple reverse stock splits reducing share count from 45.2M to 2.0M shares while losses widened substantially.
The company executed two separate reverse stock splits within seven months (1-for-249 and 1-for-60), representing a combined 1-for-14,940 consolidation that signals severe financial distress and potential delisting concerns. The Series A Preferred Stock now controls 96% of voting rights, effectively transferring corporate control away from common shareholders and creating a highly concentrated ownership structure that limits minority shareholder influence.
Revenue grew modestly to $13.9M while losses widened meaningfully to -$9.5M, indicating deteriorating profitability despite top-line growth. Current liabilities increased substantially to $12.8M while accounts receivable nearly doubled to $2.1M, suggesting potential working capital pressures. The dramatic reverse stock split activity combined with widening losses and rising current liabilities points to a company under significant financial stress requiring emergency capital restructuring measures.
Receivables surged 86.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Current liabilities surged 80.8% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 58.8% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 53.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 25.6% — deleveraging improves balance sheet strength and financial flexibility.
R&D investment increased 24.9% — signals commitment to future product development, though near-term margin impact.
Revenue growing 18.8% — solid top-line momentum, watch margins for quality of growth.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →